Advertisement
Advertisement

PASG

PASG logo

Passage Bio, Inc. Common Stock

11.52
USD
Sponsored
+0.79
+7.36%
Jan 30, 15:59 UTC -5
Closed
exchange

After-Market

10.51

-1.01
-8.77%

PASG Earnings Reports

Positive Surprise Ratio

PASG beat 13 of 23 last estimates.

57%

Next Report

Date of Next Report
Mar 02, 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$2.62
Implied change from Q3 25 (Revenue/ EPS)
--
/
+7.38%
Implied change from Q4 24 (Revenue/ EPS)
--
/
-34.50%

Passage Bio, Inc. Common Stock earnings per share and revenue

On Nov 10, 2025, PASG reported earnings of -2.44 USD per share (EPS) for Q3 25, beating the estimate of -2.85 USD, resulting in a 14.57% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +14.84% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analysts forecast an EPS of -2.62 USD, with revenue projected to reach -- USD, implying an increase of 7.38% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

logo
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
logo
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
For Q3 2025, Passage Bio, Inc. Common Stock reported EPS of -$2.44, beating estimates by 14.57%, and revenue of $0.00, 0% as expectations.
The stock price moved up 14.84%, changed from $6.71 before the earnings release to $7.70 the day after.
The next earning report is scheduled for Mar 02, 2026.
Based on 8 analysts, Passage Bio, Inc. Common Stock is expected to report EPS of -$2.62 and revenue of -- for Q4 2025.
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement